AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

ABBV Quantitative Stock Analysis May 20, 2025 — 09:06 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Pim van Vliet.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Read why ABBV stock is a hold. Skip to content. ... together with the state of the stock price based on the technical analysis. Although I find AbbVie to be a very strong business that will not ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere ... ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.